Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia

• Published in: International journal of hematologic oncology Vol. 9; no. 3; p. IJH28
• Main Authors: Underwood, Brynne, Zhao, Qiuhong, Walker, Alison R, Mims, Alice S, Vasu, Sumithira, Long, Meixiao, Z Haque, Tamanna, Blaser, Bradley W, Grieselhuber, Nicole R, Wall, Sarah A, Behbehani, Gregory K, Blachly, James S, Larkin, Karilyn, Byrd, John C, Garzon, Ramiro, Wang, Tzu-Fei, Bhatnagar, Bhavana
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 04-09-2020
• Subjects: acute lymphoblastic leukemia; adolescent young adult; Age; Cancer; Chemotherapy; Family medical history; Leukemia; Lymphoma; Patients; Pediatrics; peg-asparaginase; Risk factors; Short Communication; Thromboembolism; Thrombosis; venous thromboembolism; Young adults; United States > US; risk factors; adolescent young adult; acute lymphoblastic leukemia; peg-asparaginase; venous thromboembolism
• ISSN: 2045-1393; 2045-1407
• DOI: 10.2217/ijh-2020-0009

There are limited data describing incidence of symptomatic venous thromboembolism (VTE) in adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) patients receiving peg-asparaginase.
Single-institution retrospective analysis of 44 AYA ALL patients treated with peg-asparaginase. Rates of VTE and proposed risk factors were assessed.
18 patients (41%) had a symptomatic VTE following peg-asparaginase. The cumulative incidence rate was 25% (95% CI: 13–38%) within 30 days of the initial dose. Personal history of thrombosis was statistically significantly associated with an increased risk of VTE with HR of 2.73 (95% CI: 1.40–5.33, p = 0.003) after adjusting for gender.
These data indicate a high rate of VTE in the AYA ALL population following treatment with peg-asparaginase.